NCT03783403
Recruiting
December 21, 2018
June 16, 2022
Brief summary:
The purpose of this study is to evaluate the safety, tolerability, and preliminary clinical activity of CC-95251 as a single agent and in combination with cetuximab and rituximab in participants with advanced solid and hematologic cancers.
N/A
Arm | Intervention/treatment |
---|---|
Experimental: CC-95251 |
Drug: CC-95251 Specified dose on specified days |
Experimental: CC-95251 in combination with cetuximab |
Drug: CC-95251 Specified dose on specified days Drug: Cetuximab Specified dose on specified days |
Experimental: CC-95251 in combination with rituximab |
Drug: CC-95251 Specified dose on specified days Drug: Rituximab Specified dose on specified days |
Inclusion Criteria: Progressed on standard anticancer therapy or for whom no other approved conventional therapy exists and have histological or cytological confirmation of advanced unresectable solid tumors, advanced unresectable colorectal cancer, or squamous cell carcinoma of the head and neck, or CD20-positive non-Hodgkin's lymphoma, or diffuse large B cell lymphoma, or follicular lymphoma Solid tumors must have at least one site of measurable disease as determined by RECIST v1.1 Eastern cooperative oncology group performance status of 0 or 1 Exclusion Criteria: High-grade lymphomas (Burkitt's or lymphoblastic) Has cancer with symptomatic central nervous system (CNS) involvement History of class III or IV congestive heart failure (CHF) or severe non-ischemic cardiomyopathy, unstable angina, myocardial infarction, or ventricular arrhythmia within the previous 6 months Other protocol-defined inclusion/exclusion criteria apply
Contact: BMS Study Connect Contact Center www.BMSStudyConnect.com 855-907-3286 Clinical.Trials@bms.com
Contact: First line of the email MUST contain the NCT# and Site #.
United States, Alabama
University of Alabama Birmingham
Birmingham
United States, Arizona
HonorHealth Research Institute
Scottsdale
United States, California
UC Davis Medical Center
Sacramento
United States, California
UC Davis Medical Center
Sacramento
United States, Missouri
Washington University School of Medicine
Saint Louis
United States, Missouri
Washington University School Of Medicine
Saint Louis
United States, New York
NYU Langone Laura and Isaac Perlmutter Cancer Center
New York
United States, New York
NYU Langone Laura and Isaac Perlmutter Cancer Center
New York
United States, North Carolina
Levine Cancer Institute
Charlotte
United States, Oklahoma
University of Oklahoma Peggy and Charles Stephenson Cancer Center
Oklahoma City
United States, Oklahoma
University of Oklahoma Peggy and Charles Stephenson Cancer Center
Oklahoma City
United States, Oregon
Providence Cancer Center/Earle A. Chiles Res. Inst.
Portland
United States, Pennsylvania
University of Pittsburgh Medical Center - Cancer Pavilion
Pittsburgh
United States, Pennsylvania
University of Pittsburgh Medical Center - Cancer Pavilion
Pittsburgh
United States, Tennessee
Tennessee Oncology
Nashville
United States, Tennessee
Tennessee Oncology
Nashville
United States, Texas
The University of Texas - MD Anderson Cancer Center
Houston
United States, Texas
The University of Texas - MD Anderson Cancer Center
Houston
United States, Texas
South Texas Accelerated Research Therapeutics
San Antonio
United States, Texas
South Texas Accelerated Research Therapeutics
San Antonio
Australia, Victoria
Austin Health - Austin Hospital
Heidelberg
Australia, Victoria
Local Institution - 301
Heidelberg
Australia, Victoria
Peter MacCallum Cancer Centre
Melbourne
Canada, Alberta
Cross Cancer Institute
Edmonton
Canada, Alberta
Local Institution - 201
Edmonton
Canada, Ontario
Princess Margaret Cancer Centre
Toronto
France
Institut Bergonie
Borddeaux Cedex
France
Local Institution - 402
Borddeaux Cedex
France
Hôpital Henri Mondor
Creteil
France
Local Institution - 406
Creteil
France
Unité Lymphoïde - Hématologie 4-IPC4
Marseille
France
Hotel Dieu CHU Nantes
Nantes Cedex 01
France
Local Institution - 404
Nantes Cedex 01
France
CLCC H BecquerelHematology
Rouen
France
Local Institution - 403
Rouen
France
Gustave Roussy
Villejuif CEDEX
France
Local Institution - 401
Villejuif CEDEX
Italy
Istituto di Ematologia L. e A. Seragnoli-Azienda Ospedaliero Universitaria Policlinico S. Orsola M
Bologna
Italy
Istituto Nazionale Per Lo Studio E La Cura Dei Tumori Fondazione Giovanni Pascale
Napoli, Campania
Korea, Republic of
Local Institution - 604
Seoul
Korea, Republic of
Severance Hospital
Seoul
Korea, Republic of
Samsung Medical Center
Seoul
Korea, Republic of
Local Institution - 602
Seoul
Korea, Republic of
Seoul National University Hospital
Seoul
Korea, Republic of
Asan Medical Center
Seoul
Korea, Republic of
Local Institution - 601
Seoul
Spain
Hospital Universitario Fundacion Jimenez Diaz
Madrid
Spain
Hospital Universitario Virgen De La Victoria
Malaga
Spain
Local Institution - 502
Malaga
Spain
Local Institution - 501
Salamanca
Spain
Universitario de Salamanca - Hospital Clinico
Salamanca
United Kingdom
Derriford Hospital, University Hospitals Plymouth NHS Trust
Crownhill, Plymouth
United Kingdom
Royal Marsden Hospital
London
United Kingdom
Christie NHS Trust
Manchester
Celgene
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb